Partial
Partially Aligned
Patient Risk:
Medium
Summary
Only the first four claims and the general themes of abuse potential, fatal respiratory depression, and accidental exposure are supported by the provided EXALGO label excerpts. Multiple additional claims about street price, illicit market comparisons, purity, counterfeit/adulterants, and relative expensive opioid status are not supported by the provided prescribing information.
Category Scores
AbusePotentialAndAccidentalExposure
60
IllicitMarketAndPricing
10
Accurate Statements
Hydromorphone is a Schedule II controlled substance in the United States.
Supported by label excerpts in 5.1 and 9.1 (Schedule II controlled substance).
Hydromorphone has a high potential for abuse and addiction.
Supported by label excerpts in 5.1 and 9.1/9.2 (abuse liability; misuse, abuse, addiction).
Hydromorphone has accepted medical uses.
Supported/consistent with the label’s indication for management of moderate to severe pain in opioid-tolerant patients (1 Indications and Usage).
Illicit possession, distribution, or sale of hydromorphone is illegal and carries severe penalties.
Partially supported in concept by 5.1/9.1 referencing criminal diversion/misuse, but the label excerpts do not provide details about penalties.
Purity and potency of street-purchased hydromorphone are unknown, creating a high risk of overdose.
Not directly stated in the provided excerpts; however, the label warns that altered forms (crushed/dissolved/chewed) and misuse pose risk of overdose/death. The specific 'purity unknown' and 'high risk' phrasing is not explicitly supported.
Unsupported Statements
Street price of hydromorphone 2 mg can vary significantly due to location, purity, and availability.
No information about street pricing, location, purity, or availability in the provided EXALGO label excerpts.
Hydromorphone is generally considered one of the more expensive opioid medications on the illicit market.
No illicit market pricing comparisons in the provided label excerpts.
Geographic region, source of the drug, and quantity purchased influence fluctuating street prices of hydromorphone.
No street price fluctuation or geographic/source/quantity pricing factors in the provided label excerpts.
Higher purity generally commands a higher street price for hydromorphone.
No statements about purity affecting street price in the provided label excerpts.
Demand within a specific area can drive hydromorphone street prices up or down.
No statements about demand affecting illicit street prices in the provided label excerpts.
Hydromorphone, particularly in tablet form, is often more expensive per milligram than other opioids like oxycodone or even heroin.
No illicit pricing comparisons with oxycodone or heroin in the provided label excerpts.
The stated reason hydromorphone tablet form is more expensive per milligram includes its potency and controlled manufacturing.
No illicit pricing rationale, potency-per-milligram economics, or 'controlled manufacturing' explanation tied to street price in the provided label excerpts.
Purity and potency of street-purchased hydromorphone are unknown, creating a high risk of overdose.
The label excerpts warn about abuse/misuse (including crushing/dissolving/chewing) and overdose risk, but do not explicitly state that street purity/potency are unknown.
Street purchase of hydromorphone carries the potential for receiving a counterfeit product that may contain dangerous adulterants.
No counterfeit/adulterant content discussion in the provided label excerpts.
Street purchase of hydromorphone may involve incorrect dosages.
The label warns about fatal overdose risks related to misuse/alteration and dosing conversion, but does not specifically state incorrect street-purchased dosages.
Street purchase of hydromorphone may involve entirely different substances.
No statement in the provided label excerpts about street products containing different substances.
Engaging in illicit drug purchases of hydromorphone can lead to legal consequences.
The provided label excerpts reference criminal diversion/misuse, but do not explicitly address legal consequences of 'purchasing' illicit drugs.
Contradictions
Important Omissions
If the response intended to support the themes of fatal overdose/respiratory depression and accidental exposure, it omitted the label-specific mechanisms and warnings (e.g., crushing/dissolving/chewing risk; 'accidental ingestion, especially in children, can result in a fatal overdose').
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several claims are unsupported by the label excerpts and shift to illicit-market pricing/behavioral speculation. While some abuse/controlled-substance themes are consistent with label content, unsupported assertions about purity/unknown contents/counterfeits could mislead without being grounded in the provided prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many claims (street price, relative cost vs other drugs, purity-price relationships, counterfeit/adulterants, wrong substances, and legal consequences of purchasing) are not supported by the provided EXALGO prescribing information excerpts.
Suggested Improvement
Limit statements to on-label content: Schedule II status and abuse liability (5.1, 9.1, 9.2), fatal respiratory depression risk and the opioid-tolerant restriction and tablet alteration warnings (5.2, 4, 2.1, 2.6, 10), and accidental exposure warning (5.3, 17). Remove or rephrase unsupported illicit-market pricing and counterfeit/purity claims.